I brought up leronlimab with a healthcare/biotech columnist at Bloomberg News a couple of months ago. His article in June was about focusing on therapeutics over vaccines, and I just asked if he had heard of leronlimab. He basically said all he had seen was anecdotal and was awaiting the trial data. He wasn't rude or dismissive, just waiting for real data.
Fast forward to today, I ask him what he thought of the data, and linked to the Targeted Oncology piece that does a good job explaining it in a positive light. The response today, two months later, after trial data came out, was
"I haven't been following this particular drug closely." and then a little about how it's a good rule of thumb to look at the primary endpoint rather than try and dig for positives in the secondary endpoint data.
All of this is fair. He doesn't know much, and wasn't trying to shit on CYDY or leronlimab, it's just indicative of where we are in the overall media landscape. We pretty much don't exist.
The message boards live and breathe this drug/company, but it's practically invisible in all the important circles.
Fast forward to today, I ask him what he thought of the data, and linked to the Targeted Oncology piece that does a good job explaining it in a positive light. The response today, two months later, after trial data came out, was
"I haven't been following this particular drug closely." and then a little about how it's a good rule of thumb to look at the primary endpoint rather than try and dig for positives in the secondary endpoint data.
All of this is fair. He doesn't know much, and wasn't trying to shit on CYDY or leronlimab, it's just indicative of where we are in the overall media landscape. We pretty much don't exist.
The message boards live and breathe this drug/company, but it's practically invisible in all the important circles.
4
